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Genome-wide testing methods include array comparative
genomic hybridisation (aCGH), multiple gene panels,
whole exome sequencing (WE) and whole genome
sequencing (WGS). Here we introduce some of the key
ethical and social considerations relating to informed
consent for the testing of children, particularly the
management of incidental ﬁndings and variants of
unknown signiﬁcance.
INTRODUCTION
General paediatricians, neonatologists and other
non-genetic specialist clinicians now carry out
genomic investigations in children. The rapid
implementation of new genomic technologies
means clinicians are required to have the knowl-
edge and the conﬁdence to allow the discussion of
testing and its potential implications with parents
and families. Following the introduction of array
comparative genomic hybridisation (aCGH) as a
clinical investigation, studies looking at paediatri-
cians suggested that such non-genetics professionals
often lack the knowledge and conﬁdence to
provide an explanation of the proposed genetic
investigation, as a necessary preliminary to
consent.1 2 When comparing clinicians’ conﬁdence
in sharing results with patients and families follow-
ing aCGH testing, paediatricians self-reported low
conﬁdence in describing pathogenic results and var-
iants of unknown signiﬁcance. Many also did not
consider it pertinent—or their role—to discuss the
potential for revealing misattributed paternity and
predisposition to adult-onset disease.3
Conﬁdence in describing and managing the
results of aCGH will have undoubtedly improved
with increasing familiarity, use and availability in
the clinical setting. However, as sequence-based
technologies enter clinical practice, ﬁrst through
research projects, such as the 100 000 Genomes
Project,4 then later as validated clinical investiga-
tions, similar issues will be encountered. How can
a valid, adequately informed consent be ensured
given the volume and complexity of data generated,
particularly with regard to incidental ﬁndings and
variants of unknown signiﬁcance (see table 1)? It
may even be doubted that ‘informed consent’, as
traditionally deﬁned, is attainable in everyday
practice.5
Incidental (off-target) ﬁndings
Incidental ﬁndings (see table 1) can be assessed for
reporting according to three criteria: analytical val-
idity, clinical signiﬁcance and actionability (see
table 2).6 Yet despite meeting these criteria, we may
still question how secondary, incidental or ‘off-
target’ information is managed in children.
In the example in box 1,7 the child has been
seen by the neurologist due to a delay in her devel-
opment. Testing has inadvertently revealed a well
characterised cancer syndrome: features of the
disease can be identiﬁed using radiological and bio-
chemical tests many years before the onset of clin-
ical symptoms and with signiﬁcantly improved
prognosis. Onset is in adulthood, so reporting this
result does not have implications for Sophie at this
time. However, sharing her result may enable other
family members to undergo enhanced surveillance
or prophylaxis, which could prevent the develop-
ment of cancer, or enable it to be treated earlier
and with improved outcomes, which clearly relates
to the best interests of Sophie. Sophie’s parents, in
allowing the doctors to perform this investigation
on Sophie, may well not have considered these
potentially wide-ranging consequences of an ‘inci-
dental’ diagnosis. If they had been given informa-
tion about possible incidental ﬁndings and
understood it, would they still have proceeded with
testing?—that is, were they adequately informed?
When information of potential health or repro-
ductive consequence is discovered, how are
Box 1 Case studies
Case 1 A 4-year-old girl had a whole exome
sequence requested by the paediatric neurologist
to investigate her complex global developmental
delay. When the results showed a chromosome
3p25.3 duplication encompassing exons 2 and 3 of
the Von Hippel–Lindau (VHL) gene, she was
referred to the clinical genetic service for
assessment.8
Case 2 A term infant is 3 days old and is being
cared for in the neonatal unit following his birth.
Antenatally, he was diagnosed with gastroschisis
and complex congenital cardiac anomalies. aCGH
(array comparative genomic hybridisation) is used
to try and establish a genetic diagnosis. A
potentially pathogenic mutation is identiﬁed in the
BRCA1 gene.
Case 3 A 24-week gestation infant has aCGH
performed as part of a small for gestational age
assessment. At 1 week, the infant remains unwell
with sepsis and necrotising enterocolitis. aCGH
reveals a microdeletion associated with increased
risk of autism and schizophrenia. The neonatal
intensive care unit staff wonder if this should be
revealed to the infant’s parents for consideration in
decision-making about continuation of care.17
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decisions about disclosure made by the professionals? Would a
decision to reveal information have consequences for Sophie’s
autonomy? A discussion about informed consent can only begin
at this point: when we consider, in context, how the consent is
obtained and what it is designed to achieve or enable.
(Informed) consent in practice
The ethical concept of ‘informed consent’ consists broadly of
two key elements.8 Medical professionals must obtain the
consent of the individual or their proxy prior to undertaking an
investigation or commencing treatment. This consent, however,
is meaningless without a sufﬁcient understanding of what is at
stake, such as what the proposed investigation or treatment
entails, the potential beneﬁts and risks, and reasonable alterna-
tives. The medical professional must ensure that the person who
will make the decision (as to whether or not to give their
consent) must be adequately informed and the professional
must provide sufﬁcient, personally tailored information, in an
appropriate format for that individual, to achieve that. The
information that is shared is decided upon according to the
needs and preferences of the particular patient or family, based
on their expressed preferences, and the assessment of the
responsible clinical team.
Informational requirements are complex and highly situated
in terms of time, place and the individual situation in question.
The informational needs of a family whose young child is
undergoing investigation for severe impairment, as in case 1,
who potentially will not attain medical decision-making auton-
omy, might differ from those such as the parents in case 2, par-
ticularly with regard to the management of incidental or
uncertain information.
In this second case, sharing this result may impact adversely
on the child’s future autonomous decision in adulthood about
whether to undergo testing or enhanced screening, when the
family history is known. The context is clearly very different
when the family is already aware of an important Mendelian
genetic risk: in the case of a strong family history of early onset
breast cancer, discovery of a genetic mutation accounting for
this might well be anticipated. As such, WG/WE approaches
must not overlook, or be seen to bypass, the well established
norm of deferring predictive testing of children for an already
known high risk of an adult-onset disease.9
If the family history is unknown, or complex, not revealing
the result denies the Mother of the child in case 2, and poten-
tially other relatives, the opportunity to (potentially) beneﬁt
from this result: the so-called ‘duty to warn’. Indeed, the investi-
gation of a child may be the only way that this important infor-
mation comes to light. It is therefore considered reasonable that
the ﬁndings of WG/WE analyses should be pursued when high
throughput clinical sequencing takes place and that any signiﬁ-
cant results should be disclosed to the parents. Where such ﬁnd-
ings are genuinely incidental and completely unanticipated, the
result is not predictive, rather truly opportunistic, and poten-
tially of real beneﬁt to the health of the child and wider family.
As such, the individual’s right to conﬁdentiality is limited in
order to realise the potential of genomic testing for broader
public good.
Managing the challenge: various approaches
Guidance from the American College of Medical Genetics and
Genomics (ACMG) caused signiﬁcant controversy through its
attempt to deﬁne which mutations found ‘incidentally’ should
be reported to the patients and families.10 Rather than dealing
with incidental information as it arises ad hoc in the bioinfor-
matic processing of data obtained from WG/WE sequencing,
the ACMG approach employs a systematic screening approach
on all samples, seeking out clinically important variants in 56
genes relating to 25 disease processes. This selection of loci for
screening is based on the ACA (analytical validity, clinical signiﬁ-
cance and actionability) criteria and includes multiple cancer
predisposition syndromes, such as Lynch syndrome or Von
Hippel–Lindau syndrome, in addition to familial hypercholes-
terolaemia and cardiac genetic syndromes such as long QT syn-
drome, or hypertrophic cardiomyopathy. These results, the
ACMG argued, should be revealed regardless of parental prefer-
ences regarding secondary ﬁndings ‘where there is strong evi-
dence that a secondary ﬁnding has urgent and serious
implications for a child’s health or welfare, and effective action
can be taken to mitigate that threat’.11
European guidance12 has supported this position, though it
has emphasised ‘childhood medical actionability’ and avoided
Table 1 Definitions
Classification of result Description Examples
Variation of unknown significance/
variation of uncertain significance
Genomic alterations—including copy number variations, deletions, duplications—with
unknown phenotypical correlations, or alterations for which the genes involved have not
been described. Can be stratified as likely pathological or likely benign.
Copy number variations.
Incidental finding Pathogenic genomic variation unrelated to the presenting phenotype. Cancer susceptibility gene—see
clinical case examples.




Variant is identified using a method that is evidence-based and
of sufficient sensitivity and specificity.
Use of an evidenced method, such as aCGH, WE, WG sequencing, in a laboratory
conforming to quality control standards.
Clinical
significance
The health implications of the variant that is identified—is
there a known, reported clinical correlate?
BRCA1 and risk of breast cancer.
Actionability Potential to modify the disease course when the presence of
the variant is known.
Additional screening or prophylaxis, such as serial scanning, or altered reproductive
decision-making—such as preimplantation genetic diagnosis.
aCGH, array comparative genomic hybridisation; WE, exome sequencing; WG, whole gene.
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references to a broader sense of welfare, which might be used to
justify disclosure where incidental ﬁndings have potential impli-
cations for parents and other relatives. This is indicative of a
greater emphasis on autonomy and future autonomy in Europe,
as opposed to the deference to parental authority and autonomy
of the ACMG.
Autonomy?
The approach suggested by ACMG could be seen as a call for
opportunistic screening, representing an intentional and system-
atic attempt to identify pathogenic variants in speciﬁed genes,
unrelated to the reason which prompted testing. This could be
seen as at odds with the established professional consensus that
testing in childhood for adult-onset disease should be avoided
or deferred.9 Identifying these ‘patients-in-waiting’13 can be
seen as undermining the child’’s future autonomy to decide
whether or not to be tested for disease or disease susceptibility
and may entail risk of psychological harm when status is prema-
turely revealed.14 Yet respecting the rights of children to ‘an
open future’15 can introduce signiﬁcant moral challenge.
Deﬁning the limits of this shared autonomy is difﬁcult: where a
high risk is found for an untreatable adult-onset disorder, which
may alter the reproductive decisions of parents, should the pro-
fessionals share this information? While current guidance does
not advise that such results about children be returned, some
test providers give patients and parents the opportunity to
receive predictive information about untreatable adult-onset dis-
orders,16 despite the potential for emotional harm and the
impact on consequences for future (and current) autonomy.
The role of parental preferences and autonomy is complex. In
case 3 (adapted from ref. 17) clinicians question whether deci-
sions regarding the continuation of care for an unwell, preterm
infant, might be altered if the parents knew about the presence
of a neuropsychiatric susceptibility gene. There may be a diver-
gence in how clinicians and parents feel this information should
impact on decision-making, in a context where decisions are
highly contextual and within the acceptable zones of parental
discretion. Beyond the consideration of gene–environment
(GxE) interactions, the failure to acknowledge the likely but still
poorly deﬁned role of epigenetic factors limits the recognition
of the complexity of this supposed prognostic information.
It is generally acknowledged that competent adults have a
right to remain ignorant with regard to genetic information
about themselves.18 This supports the ethical principle of
autonomy, allowing individuals to remain the authors of their
own lives. Yet whether this right should extend to parents when
children undergo genome-wide testing is unclear: there are dif-
ferent perspectives on this. The informational privacy of chil-
dren must be balanced with the need for parents to act in the
best interests of their children, with beneﬁcence (on the part of
the parent, proxy or professional) rather than autonomy acting
as the guiding principle. Giving parents the option of not being
informed of any clinically relevant ﬁndings regarding the health
of their child ignores this parental responsibility.19 Whether
hypothetical ‘advance instructions’ about how to respond to a
range of possible ﬁndings would be considered as valid is
dubious. Perhaps there is no parental right to ignorance about
information that may stubstantially beneﬁt one’s child—parents
must be seen to act in the best interests of their child, and when
they are thought not to be doing so (in conﬂict with the clinical
team), this could constitute a safeguarding concern. To assert
the ‘right not to know’ may be incoherent when it is not yet
known that there is anything to (not) know, presenting a chal-
lenge to how advance instructions and preferences can be mean-
ingfully established and respected.
Possible solutions
Clinician-led approaches include attempts to use the model of
‘generic’ consent.19 By providing information in general cat-
egories, the aim is to avoid the unhelpful—indeed potentially
paralysing—effects of information overload, while still provid-
ing sufﬁcient information for the making of decisions.20 Largely
these attempts have been based around a categorical approach
to unanticipated ﬁndings, based around clinical actionability.
Adopting this approach, results of unknown clinical signiﬁcance
would not be reported. This acknowledges the anxiety-
provoking and time-consuming nature of discussing vast
numbers of variants of unknown or uncertain signiﬁcance,
recognising that it may not be possible to report every potential
ﬁnding. The acceptability of this to parents, and to patients
themselves, has yet to be explored in practice, but such
clinician-led ﬁltering could be represented as a return to medical
paternalism that disempowers families and patients. The role of
parents and carers in deﬁning the types of results that might be
reported back to them is starting to be explored. As indicated
above, however, the value of hypothetical decisions, made in
advance, is unclear.
Highlighting the proposed beneﬁts of a test provides a useful
starting point from which to explore the key issues when per-
forming genome-wide investigations. Describing the potential
categories of results allows clinicians and parents to be clear
about the types of information genomic tests can generate.
Proposed minimal requirements for consent21 when whole-
genome sequencing is undertaken in the clinical setting are
helpful (see table 3). However, deﬁning the ‘disadvantages, risks
and complications’ remains vague and offers little support to
non-genetics clinicians about the sort of issues we should high-
light and discuss in the clinical setting when testing is being con-
sidered and undertaken. While empirical evidence about the
informational needs of families undergoing whole-genome
sequencing is awaited, it would seem prudent to provide infor-
mation about the risk of incidental ﬁndings, variants of uncer-
tain signiﬁcance and the potential need for the testing of family
members, particularly the parents and siblings of the index case,
and including the potential for identifying misattributed pater-
nity. Parental samples are required for the interpretation of
aCGH data in 10% of cases22 and this is likely to be much
greater in WG or WE sequencing. Where laboratories employ
Table 3 Proposed minimal requirements for consent in whole
genome sequencing22
Scope The scope of the test
Description Brief description of the test process.
Benefit Benefits that we expect.
Risk Possible disadvantages, risk and complications.
Voluntary Voluntary nature of the test.
Refusal Possibility of refusal at any time, without consequences for
clinical or social care.
Alternative test Description of alternative diagnostic tests, if available.
Confidentiality Description of the measures taken to ensure confidentiality,
and the privacy of the results now and in the future.
Future use Destination and potential further use of samples, such as
research, retesting with further phenotypical information,
retesting as genomic databases become more extensive.
Incidental
findings
Management of incidental findings, and right not to know.
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ACMG guidance and systematically ‘search’ for off-target ﬁnd-
ings, this should be discussed and explained clearly. When
parents themselves are undergoing testing to ascertain the
potential meaning of a result in a child, the implications of
revealing, or systematically analysing off-target secondary var-
iants must also be emphasised and considered.
As more genomic sequencing is performed, our ability to
interpret ﬁndings, relating genotypical information to potential
phenotypes, will continue to improve and develop.
Interpretation depends heavily on publicly available genomic
databases, which are continually updated with increasingly com-
prehensive data. It has been argued that clinicians have a respon-
sibility to recontact patients when new information, regarding
the interpretation of genetic information, becomes available.23
No consensus currently exists about how this should be
managed, and addressing such concerns is likely to be particu-
larly challenging in the paediatric setting: how should informa-
tion be communicated to children gaining competency and
autonomy with regard to their own health? Any duty to recon-
tact children in adulthood, to ensure the appropriate communi-
cation of results or to reconsider the signiﬁcance of variants of
unknown signiﬁcance in the light of new information, would be
challenging from logistical, economic and legal perspectives.24
However it is important that families are aware that the implica-
tions of information they receive may change over time.
Conclusion and future work
As genetic investigations move from the specialist to the general
medical setting, clinicians must be conﬁdent in supporting
patients and parents to achieve an adequate understanding to
enable them to beneﬁt from new genetic technologies. A reason-
able approach has to be developed that neither denies patients
access to an important diagnostic tool because families are
deemed to have inadequate understanding, nor restricts the
mainstreaming of genomic medicine by making clinicians feel
that the demands of informed consent are impossible to fulﬁl.
Parents (and patients too, where feasible) need a pragmatic
understanding that genomic testing might yield clear diagnostic
information, it might add nothing, it might identify a genetic
change of uncertain signiﬁcance or it might, indeed, identify an
incidental ﬁnding of unexpected signiﬁcance with consequences
for the child and family more broadly. It is also important to
consider the special circumstances of certain speciﬁc groups, for
example those participating in clinical research such as the
100 000 Genomes Project4 where raw data might be made avail-
able, and children who are, or may in the future be, fostered or
adopted.25
Continuing association with clinical genetics services will
facilitate clinical support in complex cases, strengthening com-
munication and education as technologies and practices develop.
Interdisciplinary empirical research into the situated bioethical
considerations that arise will be important and will inform
policy decisions about how best to support the informational
needs of patients, families and children undergoing testing.
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